Expression, Purification and Characterization of Functional Teduglutide Using GST Fusion System in Prokaryotic Cells

PURPOSE: Teduglutide is the first and only FDA-approved drug for long-term treatment of short bowel syndrome (SBS). The current study aimed to present an approach for production of teduglutide using recombinant DNA technology. METHODS: The coding gene for teduglutide was cloned into pGEX-2T vector,...

Descripción completa

Detalles Bibliográficos
Autores principales: Alizadeh, Ali Akbar, Rasouli, Saba, Jamshidi Kandjani, Omid, Hemmati, Salar, Dastmalchi, Siavoush
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tabriz University of Medical Sciences 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460804/
https://www.ncbi.nlm.nih.gov/pubmed/37646058
http://dx.doi.org/10.34172/apb.2023.064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460804/
https://www.ncbi.nlm.nih.gov/pubmed/37646058
http://dx.doi.org/10.34172/apb.2023.064

Ejemplares similares